Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Management of
HF involves accurate diagnosis and implementation of evidence-based treatment strategies. …

… , the authors estimated that digoxin therapy saves $406 million annually in total heart
failure costs (range, $106-$822 million). Importantly, digoxin therapy was cost-saving both in …

… effectiveness are reduced to a single measure, generally in a currency.We can begin to
understand the approach of costeffectiveness … Cost effectiveness in the treatment of heart failure …

… against the costs of treatment. In this study, we consider the cost effectiveness of carvedilol
in CHF using a Markov model that we developed to project outcomes and medical care costs …

… The objective of this study was to determine the effect of care in the home (CHM)
compared … heart failure (CHF) on clinical outcomes and healthcare use including a cost-effectiveness …

… Sacubitril/valsartan has been approved for use in heart failure (HF) with reduced ejection
fraction in the United States and cost has been suggested as 1 factor that will influence the use …

… In 2013, heart failure cost our healthcare system >$32 billion … costs, and comparative
cost-effectiveness of treatment strategies for patients with inotrope-dependent stage D heart failure. …

… of cardiac rehabilitation centers for patients with heart failure. Therefore, the purpose of the
present study was to perform a cost-effectiveness analysis based on the efficacy results of the …

… cost-effectiveness in the subgroups of patients with class II or class III/IV heart failure. … -term
disutility secondary to heart failure hospitalizations, the treatment had a cost per QALY gained …

Background Heart failure (HF) is a well-recognized public health concern and imposes high
economic and societal costs. Decision analytic models exist for evaluating the economic …